Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. The company is headquartered in Watertown, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2022-01-07. The firm is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. The company is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The firm is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.

Industry: Biological Products, (No Diagnostic Substances) Peers: Anika Therapeutics Inc Atara Biotherapeutics Inc BioXcel Therapeutics Inc Kalvista Pharmaceuticals Inc Eiger BioPharmaceuticals, Inc. Foghorn Therapeutics Inc Karyopharm Therapeutics Inc Prelude Therapeutics Inc Scholar Rock Holding Corp